Fennec Pharmaceuticals Inc. (FRX.TO) Research

Fennec Pharmaceuticals Inc., a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development. This product candidate is specifically engineered to protect young cancer patients from platinum-induced ototoxicity, a form of hearing loss caused by chemotherapy. Previously known as Adherex Technologies Inc., the company officially rebranded to Fennec Pharmaceuticals Inc. in September 2014.

Market snapshot

Symbol
FRX.TO
Price
$12.69
Day change
0.00%
Market cap
$258.9M
P/E ratio
-29.50x
52-week range
7.59-14.24
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Cybin Inc. (CYBN.NE)
  • Medical Facilities Corporation (DR.TO)
  • Eupraxia Pharmaceuticals Inc. (EPRX.TO)
  • Helix BioPharma Corp. (HBP.TO)
  • High Tide Inc. (HITI.V)
  • NervGen Pharma Corp. (NGEN.V)
  • OrganiGram Holdings Inc. (OGI.TO)
  • Profound Medical Corp. (PRN.TO)

Open Fennec Pharmaceuticals Inc. (FRX.TO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.